La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Couchbase a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Couchbase..

Couchbase (NASDAQ:BASE) Azioni, Catena delle Opzioni

COUCHBASE INC

Couchbase

Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.

Couchbase Inc

BASE Inc

Base Carbon Inc

Base Resources Ltd

Basel Medical Group Ltd - ordinary shares

Basel Medical Group Ltd

BASELLANDSCHAFTLICHE KANT by Basellandschaftliche Kantanalbank

Basellandschaftliche Kantonalbank

BASELODE ENERGY CORP by BASELODE ENERGY CORP.

Baselode Energy Corp

Piper Sandler analyst Alexander Goldfarb downgrades Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) from Overweight to Neutral and lowers the price target from $78 to $61.

News

Downgrades

Price Target

Analyst Ratings

TRNO

Piper Sandler Downgrades Terreno Realty to Neutral, Lowers Price Target to $61

Billionaire entrepreneur Mark Cuban&nbsp;warns of a potential economic crisis worse than 2008 if the newly imposed tariffs persist and DOGE continues its downsizing.
What Happened:&nbsp;In a series of posts on BluSky Social on Sunday, Cuban outlined a grim economic forecast if the new tariffs remain in place for several years, and if&nbsp;DOGE continues to cut and&nbsp;fire. The combination of rising costs and a shrinking government workforce could cripple the economy.
When asked about the best-case scenario by another BlueSky user, he said it would involve scrapping the April 2 tariffs by Monday, keeping only a 10% levy, and Elon Musk stepping away from DOGE. If the resulting adjustments are phased in over three years with consideration for local conditions, the economy could catch a breather. The resulting slowdown might ease interest rates, making debt more manageable.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="602" height="292" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07090221/image-65.png" alt="" class="wp-image-859928" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07090221/image-65.png 602w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/07090221/image-65-300x146.png 300w" sizes="(max-width: 602px) 100vw, 602px" /></figure>
See Also:&nbsp;<a href="https://benzinga.com/news/25/04/44658808/scaramucci-on-tariffs-there-is-stupid-and-then-there-is-donald-trump-stupid" target="_blank" rel="noreferrer noopener">Scaramucci on Tariffs: &#8216;There Is Stupid and Then There Is Donald Trump Stupid&#8217;</a>
Furthermore, the Shark Tank judge states that a narrow path to stability emerges in a "thread-the-needle" scenario. It envisions a situation where lower rates and inflation, coupled with a smaller deficit and debt, could stimulate economic growth and facilitate debt repayment. However, this scenario depends on the extension of tax cuts without any other changes.
Why It Matters: Cuban&#8217;s comments come amid a turbulent stock market caused by the newly imposed tariffs. The <a href="https://www.benzinga.com/markets/25/04/44660007/mark-cuban-says-between-free-trade-elon-musk-and-full-tariff-trump-it-is-the-president-who-will-win-as-stocks-futures-tank">stock prices </a>of major tech companies, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), have taken a significant hit due to the trade war initiated by the tariffs.
While Elon Musk has advocated for a zero-tariff policy, Cuban predicts that the President&#8217;s plan will ultimately prevail in this debate. This ongoing dispute between &#8216;Free Trade&#8217; Musk and &#8216;Full Tariff&#8217; Trump has significant implications for the future of the economy.
Meanwhile, Goldman Sachs had warned that the U.S. Recession &#8216;Countdown&#8217; has begun and raised the odds of a recession to 45% from 35%. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, declined in premarket on Monday. 
<ul>
<li>Read Next:&nbsp;<a href="https://benzinga.com/markets/25/04/44658863/peter-lynchs-advice-if-you-cant-explain-to-an-11-year-old-in-two-minutes-or-less-why-you-own-the-stock-yo" target="_blank" rel="noreferrer noopener">Peter Lynch&#8217;s Advice: &#8216;If You Can&#8217;t Explain to an 11-Year-Old in Two Minutes or Less Why You Own the Stock, You Shouldn&#8217;t Own It&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

AAPL

AMZN

MSFT

Mark Cuban Warns Of A Crisis 'Far Worse' Than 2008 If Trump's Tariff Turmoil And Elon Musk's DOGE Moves Continue

WIIM

AKAM

APPS

ARQQ

ASML

ATGL

CDNS

CMBM

CMTL

COHR

CSAI

DATS

DELL

DGNX

ENPH

ENTG

FICO

FSLY

GDDY

GOOG

GOOGL

GWRE

INTC

INTZ

IVDA

LAES

LDTC

LITE

LMFA

MASS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MPWR

MRVL

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NTNX

NVDA

OKTA

OLED

OUST

PCOR

Penguin Solutions, Inc. - Ordinary Shares

PENG

PLTR

PRSO

QCOC

QMCO

RDZN

SAIL

SEDG

SHOP

SMTK

SNCR

SNOW

SNPS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

STAI

TDTH

TTAN

UBXG

XTKG

ZETA

Shares of technology companies are trading lower as President Trump's announcement of sweeping tariffs continues to rattle global markets and raise uncertainty regarding tech supply chains.

Trading Ideas

ICCT

iCoreConnect Shares Halted On Circuit Breaker To The Downside, Stock Now Up 21%

BJDX

Bluejay Diagnostics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 154.7%

Macro Economic Events

Global

Economics

President Trump Says Countries All Over World Talking To Us; Tough But Fair Parameters Are Being Set; Spoke To Japan, Japan Sending Negotiating Team

Lexeo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) on Monday released interim data across all dose cohorts of LX2006 for Friedreich ataxia (FA) cardiomyopathy, a serious heart condition in FA patients with a rare, <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">inherited neuromuscular disorder</a>.&nbsp;
In both the Lexeo-sponsored SUNRISE-FA Phase 1/2 trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial, treatment with LX2006 was associated with clinically significant improvements in cardiac biomarkers and functional measures, and increased frataxin protein expression was observed in all <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44662261/lexeo-therapeutics-announces-positive-interim-phase-12-data-for-lx2006-in-friedreich-ataxia-cardio" rel="noreferrer noopener">participants with cardiac biopsies</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44652694/roche-plans-to-start-phase-3-study-for-alzheimers-prospect-this-year-presents-new-data-from-phase-2-study" rel="noreferrer noopener">Roche To Start Phase 3 Study For Alzheimer&#8217;s Prospect This Year After New Data From Phase 2</a>
Left ventricular mass index (LVMI), a surrogate of left ventricular hypertrophy and a predictor of cardiac morbidity and mortality in adults with hypertension:
<ul>
<li>5 of 6 participants achieved >10% improvement by a 12-month visit or sooner</li>
<li>As of the latest visit, 5 of 6 participants achieved LVMI measurements within the normal range.</li>
<li>27% mean improvement in LVMI as of the latest visit</li>
<li>25% mean improvement in LVMI by a 12-month visit or sooner</li>
<li>Participants treated in Cohorts 2 and 3 (mid- and high-dose) demonstrate greater, dose-dependent improvement at earlier time points relative to Cohort 1 (low-dose)</li>
</ul>
Secondary cardiac biomarkers, functional measures, and patient-reported outcomes:
<ul>
<li>10 of 12 participants achieved a reduction in lateral wall thickness (LWT) at the latest visit.</li>
<li>11 of 12 participants achieved >25% reduction in high-sensitivity troponin I at the latest visit.</li>
<li>The majority of participants showed improvements across functional measures.</li>
</ul>
Cardiac frataxin expression (assessed in SUNRISE-FA trial only; n=8):
<ul>
<li>All participants achieved increases in frataxin protein expression at 3 months</li>
<li>Dose-dependent increases were observed across cohorts on average, with a 115% mean increase in Cohort 3 (n=4)</li>
</ul>
In Q2 2025, Lexeo expects to begin enrollment in a prospective natural history study, serving as a concurrent external control arm for the registrational study.
The company expects to initiate a registrational study by early 2026, with a potential efficacy readout in 2027.
Price Action: LXEO stock is up 7.40% at $2.51 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" target="_blank" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

LXEO

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson &amp; Johnson company, has received European Commission (EC) marketing authorization of&nbsp;the subcutaneous (SC) formulation of RYBREVANT&#xAE; (amivantamab), in combination with&nbsp;LAZCLUZE&#xAE; (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon&nbsp;19 deletions or exon 21 L858R substitution mutations. Additionally, it is approved as a&nbsp;monotherapy for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after the failure of platinum-based therapy.
Subcutaneous amivantamab is co-formulated Halozyme's ENHANZE&#xAE; drug delivery technology.

HALO

Halozyme Therapeutics Announced That Janssen-Cilag International NV, A J&J Company, Has Received European Commission Marketing Authorization Of The Subcutaneous Formulation Of RYBREVANT, In Combination With LAZCLUZE, For The First-Line Treatment Of Adult Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions Or Exon 21 L858R Substitution Mutations

Bernstein analyst Daniel Roeska downgrades General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Market Perform to Underperform and lowers the price target from $50 to $35.

Bernstein Downgrades General Motors to Underperform, Lowers Price Target to $35

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.darlingii.com%2F&amp;esheet=54234548&amp;newsitemid=20250407670003&amp;lan=en-US&amp;anchor=Darling+Ingredients+Inc.&amp;index=1&amp;md5=ede2e4d88790d4ff47d58c65c7a5e044">Darling Ingredients Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) today issued the following statement regarding tariffs.
Darling Ingredients is a resilient global business, operating 260 facilities across five continents. Our scale, geographic diversity and integrated supply chain enable us to adapt quickly to changing market dynamics and continue meeting customer needs around the world.
The vast majority of the ingredients we produce in the U.S. are utilized domestically, with minimal exposure to exports impacted by current tariffs, including to China. We do not believe these current developments are material to our business.
Historically, we have managed through many periods of volatility in finished product markets driven by commodity fluctuations. We view this situation no differently and, as always, are making the necessary adjustments to maintain and protect our margins.
We expect global trade flows to adjust and normalize over time. With our strong international footprint and market agility, Darling Ingredients remains well positioned to navigate shifts in trade policy and continue delivering value to customers and stakeholders.

Darling Ingredients Issues Statement On Tariffs; Says "We Expect Global Trade Flows To Adjust And Normalize Over Time. With Our Strong International Footprint And Market Agility, Darling Ingredients Remains Well Positioned To Navigate Shifts In Trade Policy And Continue Delivering Value To Customers And Stakeholders."

HII (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) and HD Hyundai Heavy Industries (HHI), two of the world's leading shipbuilders across multiple classes of ships, signed a memorandum of understanding (MOU) today to explore opportunities to collaborate on accelerating ship production in support of defense and commercial shipbuilding projects. The signing ceremony took place in HII's booth at Sea Air Space, the largest global maritime expo in North America, and was attended by HII Executive Vice President and President of Ingalls Shipbuilding Brian Blanchette and Won-ho Joo, chief executive of the naval &amp; special ship business unit at HHI.

HYMTF

HII And HD Hyundai Heavy Industries Sign MOU To Explore Opportunities To Collaborate On Accelerating Ship Production In Support Of Defense And Commercial Shipbuilding Projects

Wells Fargo analyst John Kilichowski initiates coverage on Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) with a Overweight rating and announces Price Target of $18.

Initiation

NTST

Wells Fargo Initiates Coverage On Netstreit with Overweight Rating, Announces Price Target of $18

Brings a Wealth of Managerial Experience and Track Record
RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) (TASE:XTLB.TA) (the "Company" or "XTL") announced today the appointment of Noam Band as the Company's new Chief Executive Officer. Shlomo Shalev will continue as the Chairman of the Board of Directors.
Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) (TASE:GIX), a publicly traded technology company specializing in online marketing, and as the Chief Executive Officer of Dotomi (acquired by ValueClick), where he oversaw operations and strategic initiatives in the digital marketing space. From 2020 through its acquisition in 2023 he served as a board advisor to 7digital Group plc (formerly AIM: 7DIG), contributing to its strategic direction and corporate governance. He has also served as the Chief Executive Officer of Monitor2Heart He holds an MBA and a B.A. in Economics from The Hebrew University of Jerusalem.

Management

XTLB

XTL Biopharmaceuticals Announces The Appointment Of Noam Band As The Company's New CEO; Shlomo Shalev Will Continue As The Chairman Of The Board Of Directors

Redburn Atlantic analyst Hamilton Faber upgrades Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Neutral to Buy and announces $100 price target.

Upgrades

ROKU

Redburn Atlantic Upgrades Roku to Buy, Announces $100 Price Target

IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) today announced it has acquired Hakkoda Inc., a leading global data and AI consultancy. Hakkoda will expand IBM Consulting's data transformation services portfolio, adding specialized data platform expertise to help clients get their data ready to fuel AI-powered business operations.
Hakkoda has leading capabilities in migrating, modernizing, and monetizing data estates and is an award-winning Snowflake partner. This acquisition amplifies IBM's ability to meet the rapidly growing demand for data services and help clients build integrated enterprise data estates that are optimized for speed, cost and efficiency across multiple business use cases.
Hakkoda also brings a strong portfolio of generative AI powered assets that can speed up data modernization projects. Their industry solutions complement and build on their consultants' deep expertise in&nbsp;industries like financial services, public sector, and healthcare and life sciences. Hakkoda will further expand IBM's ability to bring both consulting expertise and AI to clients using its AI-powered delivery platform, <a href="https://www.ibm.com/consulting/advantage">IBM Consulting Advantage</a>.

IBM Acquires Hakkoda, Expanding Data Expertise To Fuel Clients' AI Transformations; Financial Details Of The Transaction Were Not Disclosed

SuRo Capital Portfolio Investment CoreWeave Completes Largest Tech IPO Since 2021
SuRo Capital Portfolio Investment OpenAI Closes Largest Venture Raise with $300 Billion Valuation
Net Asset Value Anticipated to be $6.50 to $7.00 Per Share
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MAvSzMy0SZXYgMm10sEW3nOfiod1hEwcA0P1DpXv8Oi2CBXPRNBcGGHAdqZl01_dNaRSDL2eGp9A2qXIgWgp4g==">SuRo Capital Corp.</a> ("SuRo Capital", the "Company", "we", "us", and "our") (Nasdaq: <a href="https://www.globenewswire.com/Tracker?data=K4DrqAUxOqdjpSx36DYpreMOhF2F6EHamO_ejfDt0RotJG1Klcf_WKOnXI5ZArnm6P5-5gTd7M1Rulu9xP0GuUuBrq-Uf-zUMbwBgmZX-9VuvgQsQ3CkClHlkHRc9Nqi">SSSS</a>) today provided the following preliminary update on its investment portfolio for the first quarter ended March 31, 2025.

Guidance

SSSS

SuRo Capital Q1 2025 Preliminary Investment Portfolio Update; Net Asset Value Anticipated To Be $6.50-$7.00 Per Share

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) with a Outperform and lowers the price target from $12.25 to $10.75.

SUNS

Keefe, Bruyette & Woods Maintains Outperform on Sunrise Realty Trust, Lowers Price Target to $10.75

UBS analyst Steven Fisher downgrades Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Neutral to Sell and lowers the price target from $49 to $32.

UBS Downgrades Terex to Sell, Lowers Price Target to $32

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) with a Outperform and lowers the price target from $22 to $21.

STWD

Keefe, Bruyette & Woods Maintains Outperform on Starwood Property Trust, Lowers Price Target to $21

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains NexPoint Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NREF#NYSE">NREF</a>) with a Market Perform and lowers the price target from $16 to $15.

NREF

Keefe, Bruyette & Woods Maintains Market Perform on NexPoint Real Estate, Lowers Price Target to $15

Contracts

Press Releases

Couchbase Announces New Employee Inducement Grants

Couchbase Introduces Capella AI Services to Streamline Development of Agentic AI Applications

Earnings

Couchbase Announces Third Quarter Fiscal 2025 Financial Results

Couchbase to Present at Upcoming Investor Conference

Couchbase Announces Date of Fourth Quarter and Full Year Fiscal 2025 Financial Results Conference Call

Couchbase Capella to Accelerate Agentic AI Application Development with NVIDIA AI

Couchbase Announces Fourth Quarter and Fiscal 2025 Financial Results

Couchbase Unveils Edge Server to Help Organizations Solve Real-World Edge Application Challenges

Comments

Couchbase

Couchbase (BASE) Opzioni

Couchbase (NASDAQ:BASE) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO